| Name | Walgreens #4435 |
|---|---|
| Organization Name | Walgreen Co |
| Location | 4420 E Brown Rd, Mesa, Arizona 85205 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (480) 396-8193 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) today reported a net loss of $6.3 million, or $0.30 per basic and diluted share, for the three months ended June 30, 2009, compared with a net loss of $4.9 million, or $0.25 per basic and diluted share, for the comparable period in 2008.
The Food and Drug Administration (FDA) in the United states is considering creating a new category of drugs.
Eli Lilly and Company and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes.
A new study suggests that fetal alcohol exposure reduces the taste system's responsiveness to the bitter flavor and burning sensation of many varieties of alcoholic beverages.
› Verified 6 days ago
| NPI Number | 1306851647 |
| Organization Name | WALGREEN CO |
| Doing Business As | WALGREENS #04435 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 4420 E Brown Rd, Mesa, AZ 85205 |
| Phone Number | 480-396-8193 |
News Archive
Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) today reported a net loss of $6.3 million, or $0.30 per basic and diluted share, for the three months ended June 30, 2009, compared with a net loss of $4.9 million, or $0.25 per basic and diluted share, for the comparable period in 2008.
The Food and Drug Administration (FDA) in the United states is considering creating a new category of drugs.
Eli Lilly and Company and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes.
A new study suggests that fetal alcohol exposure reduces the taste system's responsiveness to the bitter flavor and burning sensation of many varieties of alcoholic beverages.
› Verified 6 days ago
News Archive
Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) today reported a net loss of $6.3 million, or $0.30 per basic and diluted share, for the three months ended June 30, 2009, compared with a net loss of $4.9 million, or $0.25 per basic and diluted share, for the comparable period in 2008.
The Food and Drug Administration (FDA) in the United states is considering creating a new category of drugs.
Eli Lilly and Company and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes.
A new study suggests that fetal alcohol exposure reduces the taste system's responsiveness to the bitter flavor and burning sensation of many varieties of alcoholic beverages.
› Verified 6 days ago
Osco Drug #0980 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1951 W Baseline Rd, Mesa, Arizona 85202 Phone: (480) 456-4850 | |
Osco Drug #1002 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 9243 E Baseline Rd, Mesa, Arizona 85209 Phone: (480) 986-4660 | |
Osco Drug #1948 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 441 N Val Vista Dr, Mesa, Arizona 85213 Phone: (480) 830-5185 | |
Osco Drug #3989 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2727 N Power Rd, Mesa, Arizona 85215 Phone: (480) 396-3838 | |
Osco Pharmacy # 958 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 325 S Power Rd, Mesa, Arizona 85206 Phone: (480) 924-8928 |